Date of Award:
Master of Science (MS)
Animal, Dairy, and Veterinary Sciences
Stanley D. Allen
The growing neutropenic patient population provides an ideal target for opportunistic fungal infections. Several effective antifungal drugs are toxic at high doses and contraindicated for long-term treatment. Recombinant human granulocyte colony stimulating factor (rhG-CSF) has been shown to increase neutrophilic numbers and functions, thus providing enhanced host defense. Improved efficacy by using rhG-CSF in conjunction with various antifungal agents was the primary focus of these studies. Use of rhG-CSF in a murine model of vaginal candidiasis did not reduce vaginal colony counts, or improve vaginal histophathology scores. Administration of rhG-CSF in a murine model of pulmonary aspergillosis improved survival, clinical signs, and gross pathology and histophathology scores of the lungs, and increased weight gain. The rhG-CSF was not shown to be an effective therapeutic treatment in this model of vaginal candidiasis. The rhG-CSF was, however, an effective prophylactic treatment in this model of pulmonary aspergillosis.
Farrell, Lindi, "Use of Recombinant Human Granulocyte Colony Stimulating Factor as an Adjunct in Antifungal Chemotherapy in Various Animal Model Systems" (1995). All Graduate Theses and Dissertations. 3914.
Copyright for this work is retained by the student. If you have any questions regarding the inclusion of this work in the Digital Commons, please email us at .